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Metabolomics Investigation 
Reveals Metabolite Mediators 
Associated with Acute Lung Injury 
and Repair in a Murine Model of 
Influenza Pneumonia
Liang Cui1,*, Dahai Zheng1,*, Yie Hou Lee1,*,†, Tze Khee Chan1,2, Yadunanda Kumar1,‡, 
Wanxing Eugene Ho3, Jian Zhu Chen1,4, Steven R. Tannenbaum1,5 & Choon Nam Ong1,3,6
Influenza virus infection (IVI) can cause primary viral pneumonia, which may progress to acute lung 
injury (ALI) and respiratory failure with a potentially fatal outcome. At present, the interactions 
between host and influenza virus at molecular levels and the underlying mechanisms that give rise 
to IVI-induced ALI are poorly understood. We conducted a comprehensive mass spectrometry-based 
metabolic profiling of serum, lung tissue and bronchoalveolar lavage fluid (BALF) from a non-lethal 
mouse model with influenza A virus at 0, 6, 10, 14, 21 and 28 days post infection (dpi), representing the 
major stages of IVI. Distinct metabolite signatures were observed in mice sera, lung tissues and BALF, 
indicating the molecular differences between systematic and localized host responses to IVI. More 
than 100 differential metabolites were captured in mice sera, lung tissues and BALF, including purines, 
pyrimidines, acylcarnitines, fatty acids, amino acids, glucocorticoids, sphingolipids, phospholipids, etc. 
Many of these metabolites belonged to pulmonary surfactants, indicating IVI-induced aberrations of 
the pulmonary surfactant system might play an important role in the etiology of respiratory failure and 
repair. Our findings revealed dynamic host responses to IVI and various metabolic pathways linked to 
disease progression, and provided mechanistic insights into IVI-induced ALI and repair process.
Influenza virus infection (IVI) causes annual epidemics, which result in an estimated 1 billion infections includ-
ing 3–5 million severe cases and 250,000–500,000 mortality cases worldwide. Two therapeutic strategies, vaccina-
tion and antiviral drugs, are currently used to control IVI. However, vaccines need to be updated annually and are 
effective only if they match with the current circulating virus. Although antiviral drugs may reduce complications 
of IVI, they need to be given early during infection or used as prophylaxis, and certain strains of influenza viruses 
can develop resistance to these drugs. As a result, IVI continues to pose a major challenge to the global health-
care systems and there is an urgent need for novel treatment strategies. It has been proposed that host immune 
responses contributing to severe pathology need to be identified for developing new therapeutics, irrespective of 
the infecting strains1,2.
While the most common symptoms of IVI include fever, runny nose, sore throat, cough and fatigue, suscep-
tible populations can have a variety of more severe complications including primary viral pneumonia, which 
can progress to acute lung injury (ALI) and respiratory failure with a potentially fatal outcome3. The molecular 
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mechanisms that give rise to IVI-induced ALI are not well understood, although a prolonged and dysregulated 
inflammatory response to the infection has been suggested to be the major contributor to severe lung pathol-
ogy4,5. Macrophages are recruited to the infected lung and can induce alveolar epithelial cell apoptosis damage 
and lung injury by expressing tumor necrosis factor-related apoptosis-inducing ligand in severe IVI6,7. Similarly, 
neutrophils are also recruited to the inflamed lung during IVI, and although it can limit influenza virus replica-
tion8, uncontrolled neutrophil activation would disrupt lung homeostasis and contribute to influenza virus patho-
genesis by generating excessive reactive oxygen species and releasing harmful granule proteins9,10. Uncontrolled 
inflammatory responses can destroy alveoli, induce excessive edema and impairment of alveolar cell function11,12. 
Surfactants produced by type II alveolar epithelial cells maintain surface tension at the air–liquid interface, and 
surfactant degradation brings about high surface tension leading to pulmonary edema, marked impairment 
of gas exchange and lung mechanical disturbances. Apart from established records of surfactants being com-
prised of lipids and proteins, details to remaining components are missing13. Therefore, despite the importance of 
IVI-induced aberrations of the pulmonary surfactant system in ALI, it is poorly characterized and the underlying 
mechanisms still in need of better understanding. Furthermore, given the critical roles played by surfactants in 
maintaining pulmonary biology14, it is tempting to speculate that specific bronchoalveolar lavage fluid (BALF) 
metabolites may be perturbed and restored over the course of IVI-induced ALI.
Metabolomics, the analysis of the changing metabolite levels in biological systems in response to biological 
stimuli or perturbations, is a rapidly evolving field in systems biology15. As the final downstream products of 
gene expression, metabolites are directly linked to phenotypes, and reflect cellular activities at the functional 
level16,17. Metabolomics and lipidomics has been applied to infectious diseases to study host-pathogen interac-
tions18–21, and recently used to evaluate the efficacy of treatment in IVI-infected mice and influenza patients22,23. 
More recently, the micro-RNAs and mRNA expression levels following lung injury and tissue regeneration in 
a similar model with a different mouse strain were also measured24. In our previous study, we systematically 
characterized cytokines, proteome, and markers of macrophage and neutrophil activities in serum and BALF 
of a non-lethal murine influenza pneumonia model with infection-induced ALI25. During infections, patho-
gens often exploit host machinery that controls cellular metabolic processes to obtain nutrients and co-factors 
to proliferate, survive, and avert host immune defense. Conversely, the host regulates the metabolic machinery 
and the metabolome to defend against the pathogens, shape the immune system and establish repair. At the same 
time, the metabolome could be representative of tissue injury as a result of exaggerated inflammation. In view 
of this, we employed global metabolomics analyses of sera, lung tissues and BALF in this established non-lethal 
influenza murine model, with the aim of identifying key metabolic pathways linked to disease progression and 
understanding the molecular mechanisms of IVI-induced aberrations of the pulmonary surfactant system during 
ALI. Herein, we described the dynamics of host responses to IVI, and laid out the temporal changes occurring 
within the metabolic pathways, observing distinct metabolome changes in serum, lung and BALF indicative of 
the differences between systematic and localized host responses to IVI. Importantly, we found perturbations and 
restoration of pulmonary surfactant phospholipids and other metabolites in different phases of IVI in an ordered 
chronological sequence. The mechanisms leading to these metabolic changes were also explored.
Results
Temporal pathophysiologic profile in the non-lethal mouse model of IVI. We first established the 
temporal pathophysiologic profiles of the mouse model in response to IVI and the results were consistent with 
previous characterization of the same model25–28. Viral titers rose quickly and peaked at about 5 to 6 dpi, which 
then declined and virtually disappeared by 13 to 14 dpi. The body weight loss of the mice started at about 5 dpi and 
reached the lowest weight at around 9 to 10 dpi. IVI induces immune responses in the mice and leads to immune 
cell infiltration into the lung. Infiltration was detected at 5 to 7 dpi and increased continuously until reaching the 
peak level at 14 dpi, when most of viruses were cleared (Fig. 1). Thereafter, tissue repair and regeneration began 
to restore pulmonary homeostasis. By 21 and 28 dpi, the infiltration was significantly reduced, a reflection of lung 
tissue repair and recovery of the mice. Based on these model characteristics, serum, lung tissue and BALF samples 
were correspondingly collected at 0, 6, 10, 14, 21 and 28 dpi for the metabolomics study, representing major stages 
associated with peak viremia, body weight loss, inflammatory lung injury, and recovery phase of the infection.
Metabolic profiles of mice sera, BALF and lung tissues. In order to obtain reliable metabolic profiles 
of the samples, it is important to ensure the robustness of the analytical method. We first evaluated the stability 
and reproducibility of the LC-MS method by performing PCA on all the samples including the 6 QC samples29. 
As shown in Fig. S1, the QC samples are clustered in PCA scores plots of sera, lung tissues and BALF (Supp 
Fig. S1A–C), indicating good stability and reproducibility of the chromatographic separation during the whole 
sequence. Next, PCA scores plots were used to study metabolic profiles of the samples, and distinct temporal 
profiles of changes were observed in mice sera, lung tissues and BALF metabolomes upon IVI. PCA scores plot 
showed that metabolome changes in serum were reversible and the most predominant changes, as compared 
with controls at 0 dpi, happened at 6 dpi, indicated by the furthest cluster of mice at 6 dpi from the cluster at 0 dpi 
(Supp Fig. S1A). At 10 dpi, the changes moved back slightly, though its clustering was scattered and some data 
points (mice) moved closer to the cluster at 0 dpi. The metabolome changes returned to near control levels at 
14 dpi, revealed by the close clusters of 14 and 0 dpi, and kept at control levels at 21 and 28 dpi. In PCA scores plot 
of lung tissues, a clear time-course of metabolome changes could be observed. The changes started at 6 dpi, which 
increased continuously at 10 dpi and peaked at 14 dpi, and then moved towards the control levels at 21 and 28 dpi 
(Supp Fig. S1B). Unlike reversible changes in serum, certain metabolome changes in lung did not return to the 
control levels even at 28 dpi. Reversible metabolome changes in BALF were also observed in PCA scores plot, and 
the most predominant changes happened at 10 dpi (Supp Fig. S1C).
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Identification of significantly altered metabolites and pathways. To determine significantly differ-
ential metabolites, metabolites were filtered based on the following criteria: (i) p < 0.05 in one-way ANOVA with 
Benjamini-Hochberg Multiple Testing Correction; (ii) FC ≥ 1.5; (iii) signal intensity ≥ 20,000 counts (approxi-
mately three times the limit of detection of our LC/MS instrument)30. The structure identification of the differen-
tial metabolites was based on our published work (19), and the identification process is illustrated here with cyclic 
adenosine monophosphate (cAMP). First, the element composition C10H12N5O6P of the m/z 329.05 ion was cal-
culated based on the exact mass, the nitrogen rule and the isotope pattern by Masshunter software from Agilent 
(Supp Fig. S2A). Then, the elemental composition and exact mass were used for open source database searching, 
including HMDB (http://www.hmdb.ca/), METLIN (http://metlin.scripps.edu/) and MassBank (http://www.
massbank.jp/). Next, MS/MS experiments were performed to obtain structural information via the interpre-
tation of the fragmentation pattern of the metabolite, and the characteristic fragment ion of adenosine base 
was clearly observed in both positive (m/z 136.06) and negative (m/z 134.04) MS/MS spectra (Supp Fig. S2B). 
The MS/MS spectra of possible metabolite candidates in the databases were also searched and compared. As a 
result, the metabolite was identified as cAMP, which was finally confirmed by comparing both RT in the LC and 
MS/MS spectra with those of the standard (Supp Fig. S2C).
With above-mentioned method, 41, 55 and 69 differential metabolites were identified in sera, lung tissues and 
BALF, respectively, of which they belonged to a variety of metabolite classes (Figs 2–4, Supp Table S1). In serum, 
the major metabolite classes are acylcarnitine, fatty acid, amino acid and derivatives, sphingolipid, phospholipid 
and purine. In lung and BALF, although main metabolite classes are similar to those in the serum, the identities 
and the number of metabolites in each class are quite different. For example, a total of 26 purines and pyrimidines 
were found in lung and BALF, including purine and pyrimidine bases and derivatives, and nucleotides with one 
or two phosphate groups, while only 2 purines were found in serum. Similar to PCA scores plots, the heatmaps 
of altered metabolites showed that the changes of these metabolites were reversible in serum and BALF, with the 
most significant changes happening at 6 and 10 dpi, respectively (Figs 2 and 3). Although most of the identified 
differential lung metabolites also showed reversibility in their changes (Fig. 4), certain metabolites, especially 
acylcarnitines, still remained at an elevated level at 28 dpi. In terms of global quantitative differences, five differ-
ential metabolites were commonly identified between serum and lung, seven were common between serum and 
Figure 1. Representative images of H&E staining of lung tissue sections from mice infected with sub-lethal 
PR8 influenza A virus. Representative H&E images of lung sections showing tissue damage progression at the 
indicated time points (dpi) after influenza A infection. Scale bar = 100 μ m. Each picture is representative for 8 
mice.
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BALF, and eight were common between BALF and lung. Additionally, a group of amino acids and nucleotide 
sugars were uniquely identified in the lung.
Two pathway analysis tools, MetaboAnalyst and IPA were used to identify altered pathways related to IVI, 
and both tools provided similar results (Supp Fig. S3A,B). In MetaboAnalyst, the pathway data are derived from 
the KEGG database (www.genome.jp/kegg/). In the overview graph of pathway analysis with MetabolAnalyst 
(Supp Fig. S3A), all the matched pathways were arranged by − log(p) values from pathway enrichment analysis 
on Y-axis and pathway impact values from pathway topology analysis, which uses node centrality measures to 
estimate node importance on X-axis. The node color is based on its p value and the node radius is determined 
based on their pathway impact values31. In the bar chart of altered pathways with IPA, the Y-axis was the −log(p) 
values of each pathway calculated using right-tailed Fisher’s exact test (Supp Fig. S3B). In serum, major perturbed 
metabolic pathways included tryptophan metabolism, fatty acid β-oxidation, sphingolipid metabolism, purine 
metabolism, pantothenate and CoA biosynthesis, histamine degradation, etc (Supp Fig. S4). In BALF and lung, 
major altered metabolic pathways were purine and pyrimidine metabolism, sphingolipid metabolism, glutathione 
metabolism, fatty acid biosynthesis, fatty acid β-oxidation, arachidonic acid metabolism, and so on (Figs 5 and 6, 
Supp Figs S3 and S5). Disturbed amino sugar and nucleotide sugar metabolism pathways were uniquely identified 
in the lung. The molecular and cellular functions of BALF and lung with IPA were mainly cellular growth and 
proliferation, cellular development, free radical scavenging, DNA replication, and so on (Supp Fig. S3C), which 
are consistent with the functions identified in transcriptomics study of the model24.
Dysregulated pulmonary surfactants phospholipid hydrolysis following IVI. Surfactants are crit-
ical to pulmonary biology and influenza infections result in surfactant function impairment, leading to alveoli 
collapse and ALI14. Therefore, we focused on understanding the impact of BALF metabolome with IVI and their 
enzymatic regulation at the major metabolome shifts at 5 to 14 dpi. Mouse lung tissues for immunofluorescence 
analysis were collected at 0, 5, 9 and 13 dpi to capture enzymatic reactions potentially preceding the metab-
olism and catabolism of the metabolites. We observed significant increase of BALF LPCs and free fatty acids 
(palmitic, oleic and linoleic acids) at 6 and 10 dpi (Fig. 3) before a steady decrease following 14 dpi. The con-
comitant increase in sPLA2 and its activated form sPLA2pS505, the enzyme that hydrolyzes the sn-2 ester bond of 
Figure 2. Heat map of identified differential metabolites in serum. Each row shows ion intensity for a 
specific metabolite after mean centering and unit variance scaling of the data. Each column shows the serum 
metabolic profiles of PR8-infected mice at 0 dpi, 6 dpi, 10 dpi, 14 dpi, 21 dpi, and 28 dpi. Regions of red or blue 
indicate that the metabolite content is increased or decreased, respectively. *Common differential metabolites in 
the lung. #Common differential metabolites in bronchoalveolar lavage fluid.
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phospholipids, in bronchial epithelial cells, endothelial cells as well as cells in the lung parenchyma and alveolar 
space beginning from 5 dpi, up to 9 dpi and decreasing from 13 dpi, suggested that the enzyme could account for 
the increase in LPCs (Fig. 7A,B). A limited but similar set of lyso-phospholipids in the serum showed an opposite 
trend to that of BALF and tissues, reflecting their crucial functions in immunity and airway injury. The converse 
is true at 9/10 and 13/14 dpi as viremia recedes. LPCs induce chemotaxis of monocytes32,33, which matched with 
the immunofluorescence distribution of sPLA2 and sPLA2pS505 in regions heavily infiltrated by immune cells, as 
shown by dense DAPI staining at 9 and 13 dpi (Fig. 7A,B). We also observed increased perilipin immunostaining 
in the lipofibroblasts (Supp Fig. S6), increased tissue PCs peaking at 10 dpi (Fig. 4) and BALF MGs from 6 dpi to 
14 dpi (Fig. 3), suggesting compensatory measures to restore surfactant phospholipids. At 9 and 13 dpi, upregu-
lation of SP-A, a small hydrophobic protein of 29–36 kDa that enhances the surface tension lowering properties 
of surfactant phospholipids was observed. This coincided with an increase in corticosterone levels and upregu-
lation of its enzyme, 11-beta-steroid dehydrogenase (11β -HSD) which stimulates SP-A expression34 (Fig. 7C). 
There was a dramatic increase in aggregated SP-A levels in alveolar space and in ring-like structures surrounding 
Figure 3. Heat map of identified differential metabolites in bronchoalveolar lavage fluid. Each row shows 
ion intensity for a specific metabolite after mean centering and unit variance scaling of the data. Each column 
shows the serum metabolic profiles of PR8-infected mice at 0 dpi, 6 dpi, 10 dpi, 14 dpi, 21 dpi, and 28 dpi. 
Regions of red or blue indicate that the metabolite content is increased or decreased, respectively. #Common 
differential metabolites in serum. &Common differential metabolites in the lung.
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several alveoli at 14 dpi, plausibly a result of SP-A neutralizing and inhibiting PR8 virus35,36 and interaction with 
the other components of surfactant system. Moreover, the decrease in sPLA2 and sPLA2pS505 immunostaining at 
13 dpi coincided with a sharp increase in SP-A, plausibly reflecting the sPLA2 inhibitory effect by SP-A37,38. Taken 
together, the metabolome and companion protein data suggests IVI induced early damage of surfactants but 
restoration of surfactant phospholipids in combination with SP-A to maintain surfactant integrity at 13 dpi as the 
virus was cleared.
Discussion
ALI is a severe complication of primary influenza viral pneumonia, adversely affecting the pulmonary sur-
factant system; yet the underlying mechanisms are not well understood and currently there are still no 
pathophysiologic-driven therapeutic strategies available. We conducted metabolomics study on an established 
non-lethal mouse model of influenza pneumonia with the aim of unraveling the pathogenesis of IVI-induced 
ALI. In this model, inflammatory damage of the lung started at 5 to 7 dpi and peaked at 14 dpi, a time point when 
viral load has subsided, which strongly indicates that host factors would contribute to lung injury. In order to 
capture the dynamic metabolic responses to IVI, BALF, together with lung tissue and serum were profiled at 0, 6, 
10, 14, 21 and 28 dpi, covering the major stages of ‘maximal viremia’, ‘peak body weight loss’, ‘maximal inflamma-
tory lung damage’, as well as ‘recovery phase’ of the infection. For immunofluorescence analysis, lung tissues were 
collected at 0, 5, 9 and 13 dpi to capture enzymatic reactions potentially preceding the metabolism and catabolism 
of the metabolites. Compared to our previous analyses of cytokines, proteome and protein adducts changes in 
serum and BALF of the same mouse model25, lung tissue as well as serum and BALF at two more sampling time 
Figure 4. Heat map of identified differential metabolites in the lung. Each row shows ion intensity for a 
specific metabolite after mean centering and unit variance scaling of the data. Each column shows the serum 
metabolic profiles of PR8-infected mice at 0 dpi, 6 dpi, 10 dpi, 14 dpi, 21 dpi, and 28 dpi. Regions of red or blue 
indicate that the metabolite content is increased or decreased, respectively. *Common differential metabolites in 
serum. &Common differential metabolites in bronchoalveolar lavage fluid.
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points, 10 and 28 dpi, were included in the current study to provide a more comprehensive metabolite kinetics 
profile of IVI-induced ALI. Importantly, this approach offered novel insights into the pathological restoration 
process of the surfactant metabolome and allowed us to relate and verify changes to specific metabolite levels to 
their respective proteins.
Pulmonary surfactants are critical to pulmonary biology, consist mainly of lipids and a smaller fraction of pro-
teins, are synthesized by type II alveolar epithelial cells and lower pulmonary surface tension for efficient gaseous 
exchange. Our metabolomics analysis revealed marked differences in BALF metabolome at 6, 10 and 14 dpi fol-
lowing PR8 inoculation. As a consequence of upregulation and activation of sPLA2 at 5 and 9 dpi, we observed a 
corresponding enrichment of LPCs and fatty acids at 6 and 10 dpi before declining at 14 dpi (Fig. 3). As confirmed 
by immunofluorescence, we did not expect sPLA2 to co-localize with type II alveolar epithelial cells where sur-
factants were synthesized, but instead were expressed largely in the bronchioles (Fig. 7A,B). Phospholipid analysis 
of lung surfactant PCs using GC-MS showed that ~60% of PCs at physiological states are predominantly dipalmi-
toylphosphatidylcholine (PC 16:0/16:0), and the rest made up of 16:0/14:0, 16:0/16:1, 16:0/18:1 and 16:0/18:2 PC 
molecular species39. Interestingly, the acyl chains of many LPCs (14:0, 14:1, 16:1, 18:2) and fatty acids (palmitic, 
oleic acids) found in this study were congruent with the composition of lung surfactant PC species13,39. Thus we 
can conclude that the increase in LPCs and fatty acids is the result of PC hydrolysis by sPLA2. LPCs play crucial 
roles in ALI by affecting airway and capillary permeability40, increasing cellular permeability of alveolar type I 
epithelial cells41, inducing immune cells chemotaxis32,33 and decreased lung compliance and ventilator mech-
anisms42. Subsequent restoration of surfactant function and structural mechanisms including surfactant PCs 
is required for efficient gaseous exchange. Indeed, several lines of evidence strongly suggest the restoration of 
the surfactant system starting from 13/14 dpi. The attenuation of sPLA2 activity by SP-A37,38, the latter plausibly 
brought about by the induction of 11β -HSD which catalyzes the formation of BALF corticosterone, which led 
Figure 5. Scatter plots of nine significantly altered purines and pyrimidines in the lung. (A) Guanosine  
(B) Uridine (C) Thymidine (D) Xanthine (E) Deoxycytidine (F) Deoxyinosine (G) Guanosine monophosphate 
(H) Adenosine monophosphate (I) Cytidine monophosphate. Horizontal lines represent median value. 
*p < 0.05, **p < 0.01, ***p < 0.001, by one-way ANOVA test. The statistical comparison was with control levels.
www.nature.com/scientificreports/
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to decreased BALF LPCs; and increased BALF MGs and upregulation of perlipin A in lipofibroblasts to support 
triacylglycerols metabolism for the synthesis of surfactant PCs43, are indications of surfactant system recovery 
(Figs 3 and 7C, Supp Fig. S4). Our spatiotemporal results further demonstrate how the different lung cell types 
and compartments interact in a dynamic fashion to return surfactants to homeostatic levels.
In addition to these findings, our metabolomics analysis also uncovered novel metabolites which were asso-
ciated with surfactants. Purines and pyrimidines are important signalling molecules and 26 differential purines 
and pyrimidines were identified in lung and BALF after IVI. In signalling, purines and pyrimidines exert their 
modulating effects mainly through purinergic signalling receptors, which have been implicated in lung injury 
and in the pathogenesis of a variety of respiratory diseases44. Activated P2Y receptors could upregulate inducible 
nitric-oxide synthase expression in lung immune cells, resulting in increased reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) mediated stress in the lung45,46. Excessive production of ROS and RNS could 
attack cellular molecules like DNA, proteins and lipids to induce cellular and tissue damage, and has been impli-
cated in IVI-induced ALI47,48. Indeed, elevated levels of nitrosative deamination products of DNA, including 
uracil, hypoxanthine, inosine and xanthine, were found in both lung tissue and BALF during the infiltration of 
immune cells in our study. Furthermore, glutathione, a key antioxidant which protects cellular macromolecules 
against ROS and RNS in lung airways49,50, decreased dramatically at 6 dpi in BALF and did not start recovering 
until 28 dpi. Conversely, the oxidized form of glutathione that sequesters excess ROS, peaked at 10 dpi (Fig. 3). 
We have previously shown that the level of 3-chlorotyrosine, a protein adduct formed from interaction with nitric 
oxide and an indicator of neutrophil activity, increased and peaked at 14 dpi in serum of the same model upon 
IVI25. It had also been shown that key lung-abundant antioxidant enzymes of the model could be depleted by 
IVI28. Collectively, our metabolome results significantly add to the multicomponent composition of surfactants13.
Figure 6. Scatter plots of nine significantly altered purines and pyrimidines in bronchoalveolar lavage fluid. 
(A) Cytidine (B) Uracil (C) Uric acid (D) Uridine (E) Deoxycytidine (F) Xanthine (G) Inosine (H) Hypoxanthine 
(I) Guanosine. Horizontal lines represent median value. *p < 0.05, **p < 0.01, ***p < 0.001, by one-way ANOVA 
test. The statistical comparison was with control levels.
www.nature.com/scientificreports/
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Compared to the controls, 24 out of the 26 identified purines and pyrimidines were elevated and peaked 
between 6 to 14 dpi. Increased release of purine nucleotides from epithelial and immune cells in the airway has 
been observed during inflammation, and is believed to play an important role in the pathophysiology of chronic 
lung diseases50–52. Among these purines and pyrimidines, uridine diphosphate (UDP), peaked at 10 dpi in our 
study, could stimulate the release of antimicrobial chemokine ligand 20 and regulate immune cells recruitment in 
inflamed airways by acting on both epithelial and immune cells52. Meanwhile, adenosine monophosphate (AMP), 
which peaked at 14 dpi in our study, is a candidate biomarker of airway inflammation and the measurement of 
AMP in sputum was proposed as a non-invasive method to track this inflammation53. It is noteworthy that unlike 
most purines and pyrimidines, cAMP showed a decreased change trend and reached the lowest level at 21 dpi in 
the lung. cAMP is an important second messenger and its generation and inhibition are well-controlled by extra-
cellular first messengers, including neurotransmitters, hormones, chemokines or prostaglandins54. It regulates 
a broad range of cellular processes, including immune functions, and increased intracellular cAMP suppresses 
immune functions by decreasing inflammatory mediator generation, phagocytosis and the killing of microbes55. 
Thus, decreased cAMP level in the lung in our study might contribute to ALI by stimulating inflammation. In fact, 
it has been proposed that drugs which could increase intracellular cAMP levels may be useful to treat chemically 
induced ALI by stimulating alveolar fluid transport, inhibiting inflammation and inducing bronchodilation56.
Distinct metabolic signatures of serum, BALF and lung were observed in both PCA scores plots and heatmaps 
of the differential metabolites, with peaked metabolome changes happening at 6, 10 and 14 dpi, respectively. The 
Figure 7. Degradation and regulation of pulmonary surfactants during sub-lethal PR8 influenza infection. 
Representative immunofluorescence staining of secretory phospholipase A2 (sPLA2) (A) and its activated form, 
sPLA2p505 (B) to demonstrate surfactant PC hydrolysis to LPC progression at the indicated time points after 
influenza infection on mice. (C) Representative immunofluorescence staining of 11β -HSD on mouse lung 
sections from PR8-infected mice to demonstrate increased corticosterone production in bronchial epithelium. 
Immune cell infiltration can be observed at regions with dense DAPI stains. Scale bar = 200 μ m. Insert scale 
bar = 50 μ m. Each image is representative of 3–5 mice. BV = Blood vessel; BE = Bronchiole; P = Parenchyma.
www.nature.com/scientificreports/
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metabolome changes in serum represent systemic host responses to the infection, and although metabolic profile 
of serum generally coincided with the kinetics of viral replication and clearance, our results showed that such 
changes did not reflect the progress of lung pathology. In fact, when lung injury reached the maximal level at 
14 dpi, the metabolome changes in serum had returned to near control levels (Fig. 2). Although systemic metab-
olome changes could potentially reflect processes happening in all tissues and organs, including tissue lesions, 
organ dysfunctions, etc., it has been found that the analysis of serum/plasma is not adequate to assess the met-
abolic changes in tissues and even dramatic metabolic changes in the tissues are not necessarily observed in the 
plasma57. Conversely, the metabolome changes in lung, which represent localized host responses to IVI, reached 
the maximal levels at 14 dpi and were consistent with the progress of lung pathology. Meanwhile, the metabo-
lome changes in BALF coincided with the time course of weight loss of the mice and peaked at around 10 dpi. 
These results indicate that metabolome changes in different type of samples could provide different information 
concerning disease progression. Another metabolic profile difference between serum/BALF and lung is that both 
PCA scores plots and heatmaps revealed reversible metabolome changes in serum and BALF upon IVI, which are 
consistent with the sub-lethal model and the recovery of the mice. On the other hand, metabolome changes in 
the lung did not return to the control levels even at 28 dpi, indicating that IVI resulted in a more prolonged met-
abolic effect in the infected airways. Based on these observations, we concluded that parallel metabolic profiling 
of multiple biofluids (serum and BALF) and lung tissues in our study is necessary to capture more comprehensive 
metabolic changes of the mice which may directly relate to ALI.
In conclusion, this study is the first in providing a comprehensive description of metabolome changes in a 
mouse model of influenza pneumonia in the bronchoalveolar lavage fluid, lung and serum, tracing along the 
major stages of IVI-induced ALI. Through our approach we were able to offers mechanistic and spatiotemporal 
insights into IVI-induced surfactant disturbances and how the host responds subsequently for repair and res-
toration. In addition, other altered metabolic pathways and molecules may serve as disease-relevant targets for 
designing pathophysiologic-driven therapeutics to alleviate severe IVI.
Methods
Mouse and influenza virus. The non-lethal mouse model has been well-established25–28. Briefly, C57BL/6 
(B6) mice at 8–12 weeks of age were purchased from the Centre for Animal Resources (CARE), Singapore. 
Influenza A/Puerto Rico/8/34 H1N1 virus (PR8) was provided by Professor Vincent TK Chow (National 
University of Singapore, Singapore). Mice were infected with a sub-lethal dose of influenza virus by intra-tracheal 
administration after anesthetization. At 0, 6, 10, 14, 21 and 28 day post infection (dpi), 8 mice of each time point 
were euthanized and sera, BALF and lung tissues were collected, as indicated in previous publications25–28.
This study was carried out in strict accordance with the National Advisory Committee for Laboratory Animal 
Research (NACLAR) Guidelines (Guidelines on the Care and Use of Animals for Scientific Purposes) in facilities 
licensed by the Agri-Food and Veterinary Authority of Singapore (AVA), the regulatory body of the Singapore 
Animals and Birds Act. The protocol was approved by the Institutional Animal Care and Use Committee 
(IACUC), National University of Singapore. Mice were monitored every day after infection, and any mouse with 
30% body weight loss will be euthanatized immediately.
Sample preparation. The procedure for serum and BALF sample preparation followed our previously pub-
lished report19. Briefly, a volume of 50 μ L serum or 100 μ L BALF was thawed at 4 °C and proteins were precipitated 
with 200 or 400 μ L ice-cold methanol, which contained 5 μ g/mL 9-fluorenylmethoxycarbonyl-glycine as an inter-
nal standard. After vortexing, the mixture was centrifuged at 17,000 g for 10 minutes at 4 °C and the supernatant 
was collected and evaporated to dryness in a vacuum concentrator. The dry extracts were then resuspended in 
100 μ L of 98:2 water/methanol for liquid chromatography/mass spectrometry (LC-MS) analysis. Quality control 
(QC) samples were prepared by mixing equal amounts of serum or BALF from all the samples and processed as 
real samples. All samples were kept at 4 °C and analyzed in a random manner. The QC sample was run after each 
8 samples to monitor the stability of the system.
The procedure for lung tissue preparation followed published report with some modifications58. Briefly, a 
5 mg section of lung tissue was placed in bead-beater tube and homogenized with 100 μ L silica bead in 700 μ L of 
prechilled methanol/water (1:1) using Qiagen TissueLyser. The mixture was centrifuged at 17,000 g for 10 min 
at 4 °C and the supernatant was transferred to an Eppendorf tube. Then 700 μ L of prechilled methanol/water 
(1:1) was added to the pellet and vortexed. The mixture was again centrifuged at 17,000 g for 10 min at 4 °C and 
the supernatant was combined with the supernatant from previous step. The mixed supernatant was lyophilized 
to dryness in a vacuum concentrator. The dry extracts were resuspended in 200 μ L of 98:2 water/methanol for 
LC-MS analysis, and 20 μ L from each sample was pooled as QC samples. All samples were kept at 4 °C and ana-
lyzed in a random manner. The QC sample was run after each 8 samples to monitor the stability of the system.
Metabolomics analysis by UPLC-QTOFMS. The metabolomics analysis followed our previously pub-
lished report with some modifications19. Briefly, reversed-phase liquid chromatography (RPLC)-MS analyses 
were performed using Agilent 1290 ultrahigh pressure liquid chromatography system (Waldbronn, Germany) 
equipped with a 6520 Q-TOF mass detector managed by a MassHunter workstation. The column used for the 
separation was rapid resolution HT Zorbax SB-C18 (2.1 × 100 mm, 1.8 μ m; Agilent Technologies, USA), and the 
mobile phase was (A) 0.1% formic acid in water and (B) 0.1% formic acid in methanol. The initial condition of 
the gradient elution was set at 2% B for 2 min with a flow rate of 0.4 ml/min. A 7 min linear gradient to 70% B was 
then applied, followed by a 5 min gradient to 100% B which was held for 3 min. The sample injection volume was 
10 μ L and the oven temperature was set at 40 °C.
The electrospray ionization mass spectra were acquired in both positive and negative ion mode. Mass data 
were collected between m/z 100 and 1000 at a rate of two scans per second. The ion spray voltage was set at 
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4,000 V for positive mode and 3,500 V for negative mode. The heated capillary temperature was maintained at 
350 °C. The drying gas and nebulizer nitrogen gas flow rates were 12.0 L/min and 50 psi, respectively. Two ref-
erence masses were continuously infused to the system to allow constant mass correction during the run: m/z 
121.0509 (C5H4N4) and m/z 922.0098 (C18H18O6N3P3F24).
Data analysis and compound identification. Raw spectrometric data were analyzed by MassHunter 
Qualitative Analysis software (Agilent Technologies, US) and the molecular features, characterized by retention 
time (RT), chromatographic peak intensity and accurate mass, were obtained by using the Molecular Feature 
Extractor algorithm. The features were then analyzed by MassHunter Mass Profiler Professional software (Agilent 
Technologies, US). Only features with an intensity ≥ 20,000 counts (approximately three times the limit of detec-
tion of our LC/MS instrument) and found in at least 80% of the samples at the same sampling time point signal 
were kept for further processed. Next, a tolerance window of 0.15 min and 2 mDa was used for alignment of RT 
and m/z values, and the data were also normalized by internal standard. For statistical analysis, one-way ANOVA 
(p < 0.05) with Benjamini-Hochberg Multiple Testing Correction was employed. The fold change (FC) analysis 
was also performed between the group at each of the other time points relative to the control group to further 
filter the features and only those features with FC > 1.5 were selected as potential significantly altered metabolites. 
Unsupervised multivariate analysis principal components analysis (PCA) was performed with the Unscrambler-X 
statistical software package (CAMO software, Oslo, Norway). Supervised multivariate analysis orthogonal partial 
least-squares discriminant analysis (OPLS-DA) was performed with the SIMCA-P software (Umetrics AB, Umea, 
Sweden). The features with Variable Importance in the Projection (VIP) values greater than 1 were considered to 
be influential for the separation of samples in OPLS-DA analysis.
The structure identification of the differential metabolites was based on our published work19. Briefly, the 
element compositions of the metabolites were first calculated based on the exact mass, the nitrogen rule and the 
isotope pattern by Masshunter software from Agilent. Then, the elemental composition and exact mass were 
used for open source database searching, including LIPIDMAPS (http://www.lipidmaps.org/), HMDB (http://
www.hmdb.ca/), METLIN (http://metlin.scripps.edu/) and MassBank (http://www.massbank.jp/). Next, MS/MS 
experiments were performed to obtain structural information via the interpretation of the fragmentation pattern 
of the metabolite. The MS/MS spectra of possible metabolite candidates in the databases were also searched and 
compared. Finally, the metabolites were confirmed by comparison with the standards when they are commer-
cially available. For metabolic pathway analysis, Ingenuity Pathway Analysis software (IPA, www.ingenuity.com) 
and metaboAnalyst59 were used to identify relevant pathways.
Immunofluorescence staining. Mouse lung tissues were collected at 0, 5, 9 and 13 dpi, and processed 
as previously described60. Immunofluorescence staining was performed according to our previous published 
report28. Dissected lung were fixed in 10% formalin for at least 48 h and processed using Leica TP-1050 tissue 
processor (Leica Instruments; Oberkochen, Germany) and embedded in paraffin wax. 5 μ m-thick lung sections 
were cut, dewaxed, rehydrated in 100%, 90% and 70% absolute ethanol. Target antigen retrieval was performed 
using citrate buffer pH 6.0 (Dako Corporation, Carpinteria, CA). Buffer was pre-heated using medium high 
power microwave for 5 min and slides were immersed in sub-boiling antigen retrieval buffer for 20 min in low 
power microwave. After washing, slides were blocked with 10% serum (same host as secondary antibody) for 
1 h at room temperature. This is followed by incubation with primary antibody in closed humidified chamber 
overnight at 4 °C. After washing, slides were incubated with secondary antibody protected from light, at room 
temperature for 1 h, followed by 4’,6 diamidino-2-phenylindole (DAPI) staining and mounted in SlowFade Gold 
anti-fade reagents (Life Technologies, Gaithersburg, MD). Lung sections were immunofluorescence stained for 
secretory phospholipase A2 (sPLA2, ab58375), secretory phospholipase A2 (sPLA2phosphoS505; ab53105), Perilipin 
A (ab3526) and hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1, ab39364) (Abcam, Cambridge, MA). All 
sections were image at 5× , 10× and 40× with Mirax Midi slide scanner (Carl Ziess).
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